Children and adults aged 6 years or older with a diagnosis of atopic dermatitis (AD), may qualify to participate. Individuals must have mild to moderate AD with involvement of 3% or more body surface area (BSA). A history of AD for at least 3 months (if 6-17 years of age) or 6 months (if 18+ years of age) is required along with stable disease for the past 4 weeks with no significant flares, before screening.
Participants will receive investigational topical medication (active study drug) or placebo, via a cream. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.
Study participation will last about 8 weeks and involve about 5 visits to the study centre.